6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 19 Nov 2024
- Reporting date
- 19 Nov 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
GSK plc reports
- Company location
- London
GSK plc has filed 6,805 SEC EDGAR filings since 12 Jan 2001
SEC filing history
Showing 576-600 of 1,000 matching filings.
Per page
25
Current page
24
6-K
File 001-15170
GLISTEN TRIAL OF LINERIXIBAT MEETS ENDPOINT
- Filing date
- 19 Nov 2024
- Reporting date
- 19 Nov 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SC 13D/A
AMENDMENT TO THE SCHEDULE 13D
- Filing date
- 15 Nov 2024
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK ANNOUNCES OVERALL SURVIVAL RESULTS FOR BLENREP
- Filing date
- 14 Nov 2024
- Reporting date
- 14 Nov 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
BLOCK LISTING INTERIM REVIEW
- Filing date
- 13 Nov 2024
- Reporting date
- 13 Nov 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SC 13G/A
File 005-84251
AMENDMENT TO FORM SC 13G
- Filing date
- 12 Nov 2024
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 12 Nov 2024
- Reporting date
- 12 Nov 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK PUBLISHES PROVISIONAL 2025 DIVIDEND DATES
- Filing date
- 12 Nov 2024
- Reporting date
- 12 Nov 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TOTAL VOTING RIGHTS
- Filing date
- 01 Nov 2024
- Reporting date
- 01 Nov 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 30 Oct 2024
- Reporting date
- 30 Oct 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
3RD QUARTER RESULTS
- Filing date
- 30 Oct 2024
- Reporting date
- 30 Oct 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
NEW POSITIVE AREXVY DATA IN YOUNGER ADULTS AT RISK
- Filing date
- 24 Oct 2024
- Reporting date
- 24 Oct 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 17 Oct 2024
- Reporting date
- 17 Oct 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 16 Oct 2024
- Reporting date
- 16 Oct 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
FDA ACCEPTS NEW DRUG APPLICATION FOR GEPOTIDACIN
- Filing date
- 16 Oct 2024
- Reporting date
- 16 Oct 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 15 Oct 2024
- Reporting date
- 15 Oct 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
POSITIVE RESULTS OF ANCHOR TRIALS OF DEPEMOKIMAB
- Filing date
- 15 Oct 2024
- Reporting date
- 15 Oct 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 11 Oct 2024
- Reporting date
- 11 Oct 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 10 Oct 2024
- Reporting date
- 10 Oct 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
ZANTAC (RANITIDINE) LITIGATION SETTLEMENTS
- Filing date
- 09 Oct 2024
- Reporting date
- 09 Oct 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
POSITIVE EFFICACY DATA OF AREXVY OVER 3 SEASONS
- Filing date
- 08 Oct 2024
- Reporting date
- 08 Oct 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
4
File 001-37627
WVE - CHANGE IN BENEFICIAL OWNERSHIP
- Filing date
- 01 Oct 2024
- Reporting date
- 27 Sep 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TOTAL VOTING RIGHTS
- Filing date
- 01 Oct 2024
- Reporting date
- 01 Oct 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 24 Sep 2024
- Reporting date
- 24 Sep 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
POSITIVE EU OPINION FOR GSK LIQUID MENVEO VACCINE
- Filing date
- 24 Sep 2024
- Reporting date
- 24 Sep 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing